CV Sciences

Designed to elevate focus, mood, energy, and metabolism with clinically proven wellness ingredients Available in three variations - Clarity, Peace, and ReShape SAN DIEGO , Aug. 27, 2024 /PRNewswire/ -- CV Sciences, Inc.  (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced the launch of +PlusHLTH™, an all-new line of cannabinoid-free supplements delivering targeted formulations for optimized health, improved performance, and increased vitality. Rooted in rigorous science and fortified by clinically proven wellness ingredients, the new line is now available nationwide at select retailers and from the Company's website at https://www.pluscbdoil.com/plushlth.html. » Mehr auf prnewswire.com

CV Sciences, Inc. (CVSI) Q2 2024 Earnings Call Transcript » Mehr auf seekingalpha.com

SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2024. Second Quarter 2024 and Recent Financial and Operating Highlights Generated revenue of $4.0 million for second quarter 2024, consistent with $4.0 million for the second quarter 2023 and the first quarter 2024; Recognized gross margin of 47.0% for second quarter 2024 compared to 43.3% for the second quarter 2023 and a sequential improvement from 46.3% for the first quarter 2024; Cash balance of $0.5 million at quarter end compared to $1.3 million at the end of 2023; Further established number one position as top-selling hemp extract brand in the natural product retail sales channel, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry; Generated additional shelve placement and associated revenue after the launch of pet chews for hip and joint health and calming care chews; Entered into a financing with Streeterville for net proceeds of $0.9 million; Recognized an adjusted EBITDA loss of $6,000 for the second quarter 2024, close to achieving operating cash flow break-even; Acquired Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry, based in Colorado; and Appointed Maxim Group LLC ("Maxim") as non-exclusive financial advisor and investment banker to provide strategic financial advisory and investment banking services. » Mehr auf prnewswire.com